- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05088044
A Study to Assess the Impact of Implementing Modified Early Warning Score in Terms of Competency and Self-efficacy of Nurses at ILBS, Delhi
March 30, 2022 updated by: Institute of Liver and Biliary Sciences, India
A Quasi Experimental Study to Assess the Impact of Implementing Modified Early Warning Score in Terms of Competency and Self-efficacy of Nurses at ILBS, Delhi
In this study nurses will be taught regarding Modified Early Warning Score and how to mark the involved physiological parameters in the MEWS chart and then scoring will be given i.e MEWS score and according to the score intervention would be taken by nurses by communicating with other health team members.
this scoring will allow nurses to assess early deterioration and early ICU admission and at last nurses will be asked regarding the barriers or facilitators they faced while performing MEWS score.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
82
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anjali Gautam, BSc
- Phone Number: 01146300000
- Email: anjaligautam.9524@gmail.com
Study Locations
-
-
Delhi
-
New Delhi, Delhi, India, 110070
- Recruiting
- Institute of Liver & Biliary Sciences
-
Contact:
- Anajali Gautam, BSc
- Phone Number: 01146300000
- Email: anjaligautam.9524@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- registered nurses working in general, semi-private and private ward nurses willing to participate
Exclusion Criteria:
- registered nurses who will not be present at the time of data collection. pull out staffs.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: staff nurses
firstly pre-test would conducted for the group then after 7 days post-test would be conducted for the same group intervention which will be given: training on modified early warning score to staff nurses and marking of physiological parameters on MEWS chart
|
training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
to assess the impact of MEWS on competency and self-efficacy of nurses before and after implementing MEWS
Time Frame: 7 days
|
pre-test would be taken to assess previous level and post-test to measure the change in competency
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 11, 2021
Primary Completion (Anticipated)
April 15, 2022
Study Completion (Anticipated)
April 15, 2022
Study Registration Dates
First Submitted
October 11, 2021
First Submitted That Met QC Criteria
October 11, 2021
First Posted (Actual)
October 21, 2021
Study Record Updates
Last Update Posted (Actual)
April 8, 2022
Last Update Submitted That Met QC Criteria
March 30, 2022
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ILBS-Liver Disease-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
Foundation for the National Institutes of HealthRecruitingLiver Fat | Cirrhosis, Liver | Liver Fibrosis | NASH | Liver Inflammation | Metabolic Associated Fatty Liver Disease | Liver Steatoses | Metabolic Associated Steatotic Liver DiseaseUnited States
-
Tehran University of Medical SciencesNot yet recruitingLiver Transplant; Complications | Liver Transplant Disorder | End-stage Liver DiseaseIran, Islamic Republic of
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE...RecruitingLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Metastases | Liver Cancer | Liver Transplant Rejection | Liver SteatosesChina
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Beijing Friendship HospitalUnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver FibrosisChina
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Medical University of WarsawRecruitingEnd Stage Liver Disease | Liver Transplantation | Liver Transplant | Liver Transplant SurgeryPoland
-
Taipei City HospitalThe One Biopharmaceutical Co., Ltd.CompletedNon-alcoholic Fatty Liver Disease | Liver Fibrosis | Liver InjuryTaiwan
-
Chuncheon Sacred Heart HospitalSuspendedChronic Liver Disease | Acute Derangement of Liver FunctionKorea, Republic of
Clinical Trials on training porogram
-
Northeastern UniversityOregon Health and Science University; University of California, RiversideRecruiting
-
University of Trás-os-Montes and Alto DouroCompletedLipid Metabolism Disorders | Sarcopenia | Osteoporosis | Overweight and Obesity | Personal Satisfaction | Hypertension With Complications and Secondary HypertensionPortugal
-
New Jersey Institute of TechnologyRutgers, The State University of New JerseyCompletedHemiplegia | Hemiparesis | Cerebrovascular AccidentUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedHypertension | Diabetes | Peripheral Arterial DiseaseBrazil
-
Recep Tayyip Erdogan UniversityThe Scientific and Technological Research Council of TurkeyCompletedAthletic PerformanceTurkey (Türkiye)
-
Foundation for Atlanta Veterans Education and Research...United States Department of Defense; NYU Langone Health; University of Rochester and other collaboratorsRecruitingStress Disorders, Post-TraumaticUnited States
-
Lebanese UniversityCompletedHeart Failure | Quality of Life | Cardiac Rehabilitation | Aerobic Exercise | Exercise Intolerance | Respiratory Muscle Training | Strength Training
-
Poznan University of Physical EducationPoznan University of Medical Sciences; National Science Centre, PolandActive, not recruitingHealthy Athletes Aged 18-35 YearsPoland